Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference taking place on January 13th - 16th at the Westin St. Francis Hotel in San Francisco, CA.
加利福尼亞州南舊金山，2024年12月19日（GLOBE NEWSWIRE）——標準生物工具公司（納斯達克股票代碼：LAB）今天宣佈，其總裁兼首席執行官邁克爾·埃格霍爾姆博士將出席即將於1月13日在加利福尼亞州舊金山聖弗朗西斯威斯汀酒店舉行的第43屆摩根大通醫療年度會議，該會議爲16萬億美元。
Dr. Egholm's corporate presentation will be held on January 16th, 2024, at 9:45 a.m. PT.
埃格霍爾姆博士的企業演講將於太平洋時間2024年1月16日上午9點45分舉行。
A live audio webcast will be available to investors and other interested parties by accessing the Investor Relations page of the Company's website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
通過訪問公司網站的 「活動與演講」 的 「投資者關係」 頁面，投資者和其他感興趣的人士可以觀看網絡直播視頻。錄音將存檔，可在標準生物工具投資者關係頁面investors.standardbio.com上查閱。
About Standard BioTools Inc.
關於標準生物工具公司
Standard BioTools Inc. (Nasdaq: LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook, LinkedIn, and YouTube.
標準生物工具公司（納斯達克股票代碼：LAB）是SomaLogic Inc.的母公司，前身爲Fluidigm Corporation，擁有成熟的標準化下一代技術產品組合，可幫助生物醫學研究人員更快、更好地開發藥物。作爲領先的解決方案提供商，該公司使用其專有的SomaScan、質譜細胞術和微流控技術提供有關健康和疾病的可靠和可重複的見解，這些技術有助於將科學發現轉化爲更好的患者預後。Standard BioTools與全球領先的學術、政府、製藥、生物技術、動植物研究和臨床實驗室合作，專注於轉化和臨床研究中最緊迫的需求，包括腫瘤學、免疫學和免疫療法。在 standardbio.com 上了解更多信息，或通過 X、Facebook、LinkedIn 和 YouTube 聯繫我們。
For Research Use Only. Not for use in diagnostic procedures.
僅供研究使用。不適用於診斷程序。
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. 2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
有限使用標籤許可和其他條款可能適用：standardbio.com/legal/salesterms。
專利和許可信息：standardbio.com/legal/notices。
商標：standardbio.com/legal/商標任何其他商標均爲其各自所有者的專有財產。2024 Standard BioTools Inc.（又名 Fluidigm Corporation）。版權所有。
Investor Contact
投資者聯繫方式
David Holmes
Gilmartin Group LLC
ir@standardbio.com
大衛霍姆斯
吉爾馬丁集團有限責任公司
ir@standardbio.com
譯文內容由第三人軟體翻譯。